Quick Answer
China SXT Pharmaceuticals, Inc. reported Operating Income of -$2.68 million for fiscal year 2025.
China SXT Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$2.68M | -6.6% |
| 2024 | -$2.52M | +55.1% |
| 2023 | -$5.61M | -8.1% |
| 2022 | -$5.19M | -136.2% |
| 2021 | -$2.20M | -63.8% |
| 2020 | -$1.34M | -175.8% |
| 2019 | $1.77M | +8.4% |
| 2018 | $1.63M | +1.9% |
| 2017 | $1.60M | — |
- China SXT Pharmaceuticals, Inc. showed a decrease of -6.6% in Operating Income compared to the prior fiscal year.
- Over the 2017–2025 period, China SXT Pharmaceuticals, Inc.’s operating income has declined by 267.3% (from $1.60 million to -$2.68 million).
- The most recent figure is from China SXT Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 20-F), filed with the SEC on July 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: